Brief: Theseus Pharmaceuticals To Discontinue Enrollment In Phase 1/2 Study And Terminate Development Of The-630 In Patients With Gist
13/07/2023 21:12
July 13 (Reuters) - Theseus Pharmaceuticals Inc
THRX.O :
* THESEUS PHARMACEUTICALS TO DISCONTINUE ENROLLMENT IN PHASE
1/2
STUDY AND TERMINATE DEVELOPMENT OF THE-630 IN PATIENTS WITH GIST
* DECISION FOLLOWS TWO DOSE-LIMITING TOXICITIES RELATED TO
HAND-FOOT SKIN REACTION OBSERVED IN COHORT 7 (27 MG)
* DEVELOPMENT CANDIDATE NOMINATION FROM BCR-ABL PROGRAM ALSO
EXPECTED IN H1 2024
* $234 MILLION IN CASH, CASH EQUIVALENTS, AND MARKETABLE
SECURITIES AS OF JUNE 30, 2023; RUNWAY EXTENDED INTO 2026
* PATIENTS CURRENTLY ENROLLED IN TRIAL WILL CONTINUE TO
RECEIVE
-630 UNTIL A TREATMENT DISCONTINUATION CRITERION IS MET
Source text for Eikon: ID:nPn39JT0va
Further company coverage: THRX.O
Recent news on Theseus Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-Cidara Therapeutics, Senti Bio, Lumentum Holdings
U.S. STOCKS ON THE MOVE-Newmont Corp, Ansys, Karuna Therapeutics
Theseus Pharma rises as Concentra Biosciences agrees to take it private
Brief: Theseus Pharmaceuticals To Be Acquired by Concentra Biosciences
Brief: Theseus Pharmaceuticals Inc Says As Part Of A Reduction In Workforce, Co Terminated Employment Of Timothy P. Clackson, Co's CEO, Effective As Of Dec 7